5 September 2022 - The EMA has just modified the marketing authorisations granted to messenger RNA vaccines developed by Moderna and Pfizer BioNTech in the fight against Covid-19. 

Now their versions developed to target the original strain and the Omicron BA.1 variant are licensed in Europe. HAS analyzed them with a view to their integration into the vaccine strategy. But the examination by the EMA of the vaccines adapted to the BA.4 and BA.5 variants having been brought forward to mid-September, it is at this end that the HAS will publish an overall opinion on all the bivalent vaccines.

Read HAS press release [French]